Dedifferentiated liposarcoma (ddLPS) 8858/3


UZLX-STS5

(Synonyms: -)

HUSARC Accession Number: HU-23.22 


MDM2 amplification


  • no data online available


More information about the models can be found in the datasheets. 


If you are interested in a model, please contact the corresponding researcher directly (contact information can be found below and in the datasheet).


  • Cornillie J, Wozniak A, Li H, Wang Y, Boeckx B, Gebreyohannes YK, Wellens J, Vanleeuw U, Hompes D, Stas M, Sinnaeve F, Wafa H, Lambrechts D, Debiec-Rychter M, Sciot R, Schöffski P. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Mol Cancer Ther. 2019 Jun;18(6):1168-1178. doi: 10.1158/1535-7163.MCT-18-1045. Epub 2019 Apr 8. PMID: 30962320.
  • Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P. Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. Transl Oncol. 2014 Dec;7(6):665-71. doi: 10.1016/j.tranon.2014.09.007. PMID: 25500074; PMCID: PMC4311036.
  • Cornillie J, Wozniak A, Pokreisz P, Casazza A, Vreys L, Wellens J, Vanleeuw U, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P. In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Mol Cancer Ther. 2017 Aug;16(8):1566-1575. doi: 10.1158/1535-7163.MCT-16-0832. Epub 2017 May 31. PMID: 28566438.


Entry creation: 14.09.2021

Last entry update: 16.09.2021

Version number: #1